Clinical Trial Update: Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma [NA]

View source ↗

Summary

A clinical trial update outlines a planned first-line regimen for unresectable hepatocellular carcinoma using transarterial chemoembolization with low-dose beva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Third Affiliated Hospital, Sun Yat-Sen University | Conditions: Hepatocellular Carcinoma, Transarterial Chemoembolization | NA | Status: NOT_YET_RECRUITING